On April 9, 2026, Apotex Corp received FDA approval for a generic Adult Multiple Vitamins single-dose product, a move likely to intensify price competition within the adult multivitamin market. The approval for this comprehensive 14-ingredient formulation bolsters Apotex’s portfolio and provides a new pricing option that may pressure established players in the stabilized supply chain.